Selank Peptide in Australia: What It Is, How It Works, and How to Access It Through a GP

Selank is not yet a household name in Australia, but it is becoming a more frequent topic of conversation in telehealth and performance medicine circles. Developed by the Russian Academy of Sciences — the same institution behind Semax, another peptide with growing Australian interest — Selank has been the subject of clinical research spanning several decades.

The reason Australians are searching for it is fairly straightforward: a peptide that may support anxiety management and cognitive performance, without the dependence and sedation associated with traditional anxiolytics, is a compelling concept. Whether that concept holds up under scientific scrutiny, and how prescription access works in Australia, is what this article examines.

What Is Selank?

Selank (also identified in research literature as TP-7) is a synthetic neuropeptide derived from tuftsin, a naturally occurring immune peptide produced in the spleen. It was developed at the Institute of Molecular Genetics at the Russian Academy of Sciences and has been the subject of clinical investigation in Russia since the 1990s.

Selank is most commonly administered as an intranasal spray, though injectable formulations exist. It has been the subject of formal regulatory review in Russia since 2009 for conditions including generalised anxiety disorder, neurasthenia, and adjustment disorders — making it one of the few peptides with a formal regulatory history in a major jurisdiction, even if that jurisdiction is not Australia or the Western regulatory mainstream.

It is frequently discussed alongside Semax — the two are often studied in parallel and sometimes used together, with Semax associated with cognitive activation and Selank associated with anxiolytic and calming effects.

What Is Selank Being Studied For?

Clinical and preclinical research has investigated Selank's potential role across several areas. As with any compound that does not have TGA approval, these represent areas of scientific interest rather than established therapeutic indications.

• Anxiety support without sedation. Selank has been investigated in Russia for its potential anxiolytic effects — specifically, its capacity to modulate GABA-A receptors in a way that may reduce anxiety without the sedative, amnesic, or dependency-inducing effects associated with benzodiazepines. Russian clinical data has reported anxiolytic effects in study populations, though these studies have not been replicated in large-scale Western randomised controlled trials.
• Cognitive function and nootropic effects. Research has examined Selank's potential influence on cognitive performance, including focus, memory, and the capacity to sustain mental clarity under stress. Studies have observed increases in brain-derived neurotrophic factor (BDNF) — a protein associated with neuronal health and learning — in subjects receiving Selank.
• Mood stabilisation. Research has explored Selank's involvement in serotonin and dopamine activity, as well as its GABA-modulating effects, in the context of mood stability and resilience under chronic stress conditions.
• Immunomodulatory properties. As a tuftsin-derived compound, Selank has also been studied for potential immune-supporting properties, consistent with the known biological role of its parent molecule.

How Does Selank Differ from Traditional Anxiolytics? What Research Suggests

One of the most discussed aspects of Selank in the clinical literature is its profile compared to benzodiazepines — the most commonly prescribed class of anxiolytic medication.

Benzodiazepines work primarily by broadly potentiating GABA-A activity, which produces anxiolytic effects but also sedation, impaired motor coordination, anterograde amnesia, and — with prolonged use — physical dependence and withdrawal. These side effects are well-documented and remain a significant clinical concern.

Research on Selank suggests it may interact with GABAergic pathways in a more targeted manner. Russian clinical literature has described an anxiolytic effect without the hypnosedation, myorelaxation, or withdrawal characteristics associated with benzodiazepines. Studies to date have not demonstrated dependence or withdrawal in clinical research subjects.

It is important to be precise about what this means. The Russian clinical history, while substantial, does not represent the scale or regulatory standard of Phase III trials conducted for Western drug approval. The absence of documented dependence in existing studies does not constitute proof of safety at scale. What it represents is a profile of interest that warrants further investigation — and a clinical picture that a GP can assess in the context of an individual patient.

What Does the Science Say? Important Caveats for Australians

Selank's clinical history is centred in Russia. The compound was developed there, and most of the published research originates from Russian institutions. For Australian patients, this raises legitimate questions about evidence quality and regulatory context.

• Russian regulatory history. Selank has been subject to formal regulatory review in Russia since 2009 for generalised anxiety disorder, neurasthenia, and adjustment disorders. This represents a real clinical track record, albeit not under Western approval frameworks.
• Australian regulatory status. Selank is not TGA-approved. It is not specifically listed in the Australian Poisons Standard. It falls under general unapproved therapeutic goods regulation — meaning compounded prescription access through a GP and licensed compounding pharmacy operates within a separate regulatory framework from over-the-counter or direct-to-consumer supply.
• BDNF and neurotransmitter research. Studies have documented BDNF upregulation and modulation of serotonin, dopamine, and GABA activity in research subjects receiving Selank. These mechanistic findings are consistent across multiple studies, though long-term safety data at the population level is limited.
• What is missing. Large-scale Western randomised controlled trials. This is the honest gap in Selank's evidence base. A GP considering Selank for a patient is operating in off-label compounding territory, making an individualised clinical judgement.

Selank and Semax — Often Studied Together

If you have already been researching Semax — a related peptide from the same Russian Academy of Sciences lineage — you may have encountered the two names together. There is a reason for that.

In research and in clinical practice, Selank and Semax are frequently considered as complementary compounds. The common framing, drawn from clinical observations: Semax tends toward cognitive activation and focus, while Selank tends toward anxiolytic calm and stress resilience. When considered together, they address different dimensions of cognitive and emotional performance simultaneously. A GP assessing a patient interested in both compounds would consider them individually and together as part of a broader clinical picture.

Who Might Ask Their GP About Selank?

Under Australian regulatory frameworks, there is no approved indication for Selank. A GP prescribing compounded Selank is doing so on an individualised, off-label clinical basis. The decision belongs entirely to the prescribing practitioner.

In practice, Australian GPs working in integrative and telehealth medicine have received enquiries about Selank from adults including:

• Those managing persistent anxiety or stress who are seeking options with a different side-effect profile to conventional anxiolytics
• Professionals or high-demand individuals seeking cognitive clarity and mental resilience without pharmacological sedation
• Adults researching nootropic peptides as part of a broader performance and recovery approach
• People who have already explored Semax and want to understand the complementary compound

These are not guaranteed categories of eligibility. A GP assesses the individual — their health history, concurrent medications, clinical suitability, and the current evidence base — before prescribing. Not every enquiry leads to a prescription.

How to Access Selank Through High Performance Human

Selank may be considered within the Energy and Performance Protocol, depending on the GP's assessment of your individual clinical profile. No referral is needed. For more on the access process, see our article on how to get peptides prescribed in Australia.

The Right Way to Think About Selank

Selank sits in an interesting position in the peptide landscape. It has a longer formal clinical history than many compounds that attract interest in Australia — Russian regulatory review since 2009 is not nothing. The mechanistic research on GABA modulation, BDNF upregulation, and anxiolytic effects without dependence is genuinely interesting.

At the same time, Australians deserve an honest picture of where the evidence stands. Large-scale Western trials are absent. The FDA has flagged immunogenicity concerns for compounded formulations. Long-term safety data in humans is limited.

That balance — genuine research interest, honest acknowledgement of limitations, medically supervised access — is the framework that makes sense for Selank in Australia. GP-prescribed, pharmacy-dispensed, and guided by a clinical assessment of your individual situation.

For related reading, see: what Australian GPs say about peptide safety, GP-prescribed vs grey market peptides, and Semax in Australia.